Phase 1

4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
2
Tamsulosin HClPhase 11 trial
solifenacin succinatePhase 11 trial
Active Trials
NCT02634489Completed46Est. Jul 2009
NCT02010944Completed72Est. Nov 2012
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AdalimumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03983876Completed207Est. Dec 2019
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04965842Phase 11 trial
Active Trials
NCT03647670Completed25Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlvotechAdalimumab
PfizerPF-04965842
Astellassolifenacin succinate
AstellasTamsulosin HCl

Clinical Trials (4)

Total enrollment: 350 patients across 4 trials

PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Start: Jul 2019Est. completion: Dec 2019207 patients
Phase 1Completed

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Start: Jul 2018Est. completion: Oct 201825 patients
Phase 1Completed
NCT02010944Astellassolifenacin succinate

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Start: Sep 2012Est. completion: Nov 201272 patients
Phase 1Completed
NCT02634489AstellasTamsulosin HCl

EC905 Pharmacokinetic Profile Study

Start: Mar 2009Est. completion: Jul 200946 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space